KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.N Engl J MedPMID 38381664无 PMCID2024-Feb-290.98未发现恶性肿瘤人群证据。待处理
Safety and Tolerability of Starting Aripiprazole Lauroxil With Aripiprazole Lauroxil NanoCrystal Dispersion in 1 Day Followed by Aripiprazole Lauroxil Every 2 Months Using Paliperidone Palmitate Monthly as an Active Control in Patients With Schizophrenia: A Post Hoc Analysis of a Randomized Controlled Trial.J Clin PsychiatryPMID 38416865无 PMCID2024-Feb-280.98未发现恶性肿瘤人群证据。待处理
Feasibility of online managing cancer and living meaningfully (CALM) in Chinese patients with metastatic breast cancer: a pilot randomized control trial.Sci RepPMID 38418478PMC109022842024-Feb-280.95This is a pilot randomized controlled trial evaluating a psychotherapy (CALM) for psychological symptoms. It does not meet the core criteria: no drug intervention is present, and the primary efficacy endpoint is not time-to-event (OS, PFS, DFS, etc.). While it is a randomized oncology study in humans, it is also a pilot/feasibility study, not a definitive Phase III/IIIb or Phase II/III trial as required.待处理
Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial.NeurologyPMID 38295339PMC109629182024-Feb-270.98未发现恶性肿瘤人群证据。待处理
PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.Sci Bull (Beijing)PMID 38185589无 PMCID2024-Feb-260.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Endovascular thrombectomy plus medical care versus medical care alone for large ischaemic stroke: 1-year outcomes of the SELECT2 trial.LancetPMID 38346442无 PMCID2024-Feb-240.98未发现恶性肿瘤人群证据。待处理
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.Nat CommunPMID 38395969PMC108911182024-Feb-230.95The record is a Phase III randomized trial of a human oncology condition with time-to-event endpoints (RFS, OS) and reports a primary result. However, the intervention (autologous dendritic cell therapy) is a cell-based immunotherapy/biologic, not a conventional 'drug' (small molecule, antibody, etc.) as defined by the adjudication rules. Therefore, it fails the 'drug_intervention' criterion and is excluded.待处理
Randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery following open globe trauma: The ASCOT study.Br J OphthalmolPMID 36849205无 PMCID2024-Feb-210.98未发现恶性肿瘤人群证据。待处理
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.Clin Cancer ResPMID 38060199PMC108701152024-Feb-160.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.Clin Cancer ResPMID 38109213PMC109564032024-Feb-160.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and Taiwan.VaccinePMID 38267330无 PMCID2024-Feb-150.98未发现恶性肿瘤人群证据。待处理
Cefepime-Taniborbactam in Complicated Urinary Tract Infection.N Engl J MedPMID 38354140无 PMCID2024-Feb-150.98未发现恶性肿瘤人群证据。待处理
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients.J Infect DisPMID 37506264PMC108731772024-Feb-140.98未发现恶性肿瘤人群证据。待处理
Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur).BMC CancerPMID 38350888PMC108631182024-Feb-130.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.J Immunother CancerPMID 38346853PMC108622532024-Feb-120.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial.Acta Derm VenereolPMID 38348724PMC108756232024-Feb-120.98未发现恶性肿瘤人群证据。待处理
Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.J Clin OncolPMID 38096461无 PMCID2024-Feb-100.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.LancetPMID 38310910PMC76189652024-Feb-100.98未发现恶性肿瘤人群证据。待处理
Agreement among high-sensitivity cardiac troponin assays and non-invasive testing, clinical outcomes, and quality-of-care outcomes based on the 2020 European Society of Cardiology Guidelines.Eur Heart J Acute Cardiovasc CarePMID 38001050PMC108536902024-Feb-090.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of Dimdazenil in adults with insomnia disorder: results from a multicenter, randomized, double-blind, placebo-controlled phase III trials.SleepPMID 37875349PMC108518462024-Feb-080.98未发现恶性肿瘤人群证据。待处理
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.N Engl J MedPMID 38324483无 PMCID2024-Feb-080.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Low-Dose Edoxaban by Body Weight in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the Randomized ELDERCARE-AF Trial.J Am Heart AssocPMID 38240204PMC110561112024-Feb-060.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial.JAMA Netw OpenPMID 38335000PMC108584012024-Feb-050.98未发现恶性肿瘤人群证据。待处理
Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.LancetPMID 38281499PMC108509832024-Feb-030.98未发现恶性肿瘤人群证据。待处理
Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.OncologistPMID 37589219PMC108363242024-Feb-020.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Melatonin Supplementation for Cancer-Related Fatigue in Patients With Early Stage Breast Cancer Receiving Radiotherapy: A Double-Blind Placebo-Controlled Trial.OncologistPMID 37699115PMC108363052024-Feb-020.85The study meets the oncology, human, randomized, phase, and original result criteria, but is excluded because the intervention is a dietary supplement (melatonin), not a drug, and the primary endpoint is patient-reported fatigue, not a time-to-event efficacy endpoint.待处理
Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907).Int J Radiat Oncol Biol PhysPMID 37802225无 PMCID2024-Feb-010.85The trial is a randomized Phase III oncology study in humans with a drug intervention (ADT) and an original result. However, the primary endpoint (biochemical progression) is not one of the specified time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP) required for inclusion in this adjudication. Secondary endpoints include OS and clinical progression, but these were not primary/key secondary in the sense of driving the trial's efficacy conclusion per the abstract.待处理
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.J Clin OncolPMID 37963317无 PMCID2024-Feb-010.80The record is from a randomized Phase II/III oncology trial with a drug intervention and is an original report. However, it does not report any primary or key secondary time-to-event efficacy endpoint, such as OS, PFS, DFS, or any endpoint analyzed with Kaplan-Meier or reported as an HR. The reported outcomes are surgical pathology, safety, and histopathologic regression rates, which are not time-to-event endpoints for efficacy in the context of this adjudication.待处理
DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.J Clin OncolPMID 37992266PMC108243872024-Feb-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.JAMA OncolPMID 38095881PMC107223902024-Feb-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial.JAMA DermatolPMID 38117487PMC107338452024-Feb-010.98未发现恶性肿瘤人群证据。待处理
Allogeneic Stem Cell Therapy for Acute Ischemic Stroke: The Phase 2/3 TREASURE Randomized Clinical Trial.JAMA NeurolPMID 38227308PMC107924972024-Feb-010.98未发现恶性肿瘤人群证据。待处理
Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults.N Engl J MedPMID 38294972无 PMCID2024-Feb-010.98未发现恶性肿瘤人群证据。待处理
A randomized clinical trial of home telemonitoring in patients with advanced heart and lung diseases.J Telemed TelecarePMID 34851202无 PMCID2024-Feb0.98未发现恶性肿瘤人群证据。待处理
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel.Eur UrolPMID 37085425PMC106629352024-Feb0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Peritoneal Flap for Lymphocele Prophylaxis Following Robotic-assisted Radical Prostatectomy with Lymph Node Dissection: The Randomised Controlled Phase 3 PELYCAN Trial.Eur Urol OncolPMID 37543465无 PMCID2024-Feb0.93干预为非药物单独策略,未满足药物干预要求。待处理
Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial.J Thorac OncolPMID 37748693无 PMCID2024-Feb0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Clinical and cost-effectiveness of PCF versus ACD in the treatment of cervical brachialgia (FORVAD trial).Br J NeurosurgPMID 37807634无 PMCID2024-Feb0.98未发现恶性肿瘤人群证据。待处理
Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.Ann OncolPMID 37872020无 PMCID2024-Feb0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease.Mov DisordPMID 37886872无 PMCID2024-Feb0.98未发现恶性肿瘤人群证据。待处理
Adjunctive brexpiprazole 1 mg and 2 mg daily for Japanese patients with major depressive disorder following inadequate response to antidepressants: a phase 2/3, randomized, double-blind (BLESS) study.Psychiatry Clin NeurosciPMID 37933521PMC114886042024-Feb0.98未发现恶性肿瘤人群证据。待处理
Beinaglutide for weight management in Chinese individuals with overweight or obesity: A phase 3 randomized controlled clinical study.Diabetes Obes MetabPMID 37945546无 PMCID2024-Feb0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of moxidectin compared with ivermectin against Strongyloides stercoralis infection in adults in Laos and Cambodia: a randomised, double-blind, non-inferiority, phase 2b/3 trial.Lancet Infect DisPMID 37949090无 PMCID2024-Feb0.98未发现恶性肿瘤人群证据。待处理
Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial).Br J CancerPMID 37973958PMC108037982024-Feb0.95The trial is a randomized Phase III study in oncology with a drug intervention, but its primary efficacy endpoint (complete response during delayed phase) is a categorical, non-time-to-event outcome. There is no mention of OS, PFS, DFS, or any other time-to-event endpoint, nor any Kaplan-Meier curves or hazard ratios. Therefore, it does not meet the requirement for a time-to-event efficacy endpoint.待处理
Cost-effectiveness analysis of nivolumab versus placebo for relapsed malignant mesothelioma.Int J Clin PharmPMID 37991664无 PMCID2024-Feb0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study.Lancet Infect DisPMID 38006892无 PMCID2024-Feb0.98未发现恶性肿瘤人群证据。待处理
Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United States.Value HealthPMID 38042333无 PMCID2024-Feb0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Randomized adaptive selection trial of cryotherapy, compression therapy, and placebo to prevent taxane-induced peripheral neuropathy in patients with breast cancer.Breast Cancer Res TreatPMID 38060077PMC108409892024-Feb0.90The study is a Phase IIB randomized trial focused on preventing chemotherapy-induced peripheral neuropathy, a toxicity. The primary endpoint is a functional assessment score (FACT-NTX), which is not a survival, progression, recurrence, death, or related efficacy outcome. Therefore, it does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort.待处理
The Effects of Safinamide in Chinese and Non-Chinese Patients with Parkinson's Disease.Adv TherPMID 38070039PMC108388372024-Feb0.98未发现恶性肿瘤人群证据。待处理
Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816.Cancer SciPMID 38098261PMC108596192024-Feb0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理